All In Biotech

NDA 022172 · Cheplapharm Arzneimittel Gmbh

Seroquel Xr

Quetiapine Fumarate · Oral

Last checked: Nov 20, 2026Latest source record: Nov 15, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Nov 15, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

398

129 Phase 3, 13 recruiting

FAERS reports

166,283

129,383 serious, 22,401 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • SEROQUEL XR · QUETIAPINE FUMARATE 400MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • SEROQUEL XR · QUETIAPINE FUMARATE 200MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • SEROQUEL XR · QUETIAPINE FUMARATE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • SEROQUEL XR · QUETIAPINE FUMARATE 50MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Quetiapine" as an intervention, any sponsor and status, largest first.

All 398 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,887
  • off label use9,865
  • insomnia8,363
  • toxicity to various agents8,318
  • diabetes mellitus8,095
  • somnolence7,358
  • fatigue7,022
  • drug interaction6,787
  • weight increased6,710
  • anxiety6,689
  • nausea6,604
  • depression6,467

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,549
20051,921
20063,134
20075,530
20083,326
20097,688
20109,164
201110,170
201210,999
20134,481
20145,545
20157,047
20166,970
20178,436
20189,760
201910,016
202010,161
20219,134
20228,643
20238,868
20248,920
20258,430
20266,387

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Seroquel XR (Quetiapine Fumarate)

2024 spending

$7.5M

Beneficiaries

951

7,036 claims

Per beneficiary

$7,869

$18.88 per unit

View as table
YearSpending
2020$14,776,733
2021$12,146,599
2022$10,819,557
2023$9,338,118
2024$7,483,539

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,190 on PubMed

Sponsor: Cheplapharm Arzneimittel Gmbh

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.